Nextera
About edit
Nextera AS is a Norwegian drug discovery and target discovery company spun out from a Centre of Excellence research environment at the University of Oslo and Oslo University Hospital. The company was founded in 2009.
Technology edit
NextCore Platform edit
Nextera's proprietary discovery platform combines deep insight into disease mechanisms with unique technology innovation. The platform integrates:
- NextCore — an integrated platform for developing precision drug candidates targeting the intracellular universe of disease antigens through pHLA (peptide-HLA)
- pIX phage display technology — core technology enabling discovery of novel antibody candidates
Pipeline edit
The company is developing a pipeline of TCR-Like antibody lead candidates with:
- Exquisite specificity toward disease-specific pHLA targets
- Unique potency for targeted immunotherapy
- Applications in cancer and autoimmunity
Recent Activity edit
- November 2025: Received funding from the Norwegian Research Council through the Innovation Project for the Industrial Sector (IPN) for development of TCR-Like antibodies in autoimmune diseases
- November 2025: Presentation at PEGS Europe 2025 in Lisbon (premier annual protein engineering conference)
- CEO/CSO Geir Aage Loset chairs sessions at PEGS Europe
Strategy edit
Nextera's strategy is to discover new targets and develop cognate drugs together with partners, addressing complex diseases in major indications that are currently difficult to treat.